The inaugural meeting of the Shanghai Genomics Alliance (referred to as "Alliance") was held successfully on October 15, 2021. As the sponsor and secretary-general of the Alliance, Illumina will join hands with allies from upstream and downstream of the industry chain to bring industry innovation and application to the next level, and to promote high-quality industry development under the guidance of local government.
Under the guidance of the Shanghai Municipal Commission of Economy and Informatization, the Alliance was jointly initiated and established by Illumina, Novogene, Burning Rock Dx, Berry Genomics, Hugo Biotech, and 3D Medicines as well as Shanghai Biomedical Industry Promotion Center; nearly 60 enterprises from the industry chain joined the alliance.
China's genetic testing industry and applications have shown great potential, driven by the joint efforts of policy makers, market leaders, and technology innovators. As a global leader in sequencing and array technologies, Illumina is committed to empowering market development. Illumina is also working together with local partners to continuously expand the industrial ecosystem and incubate future stars, supporting Shanghai in building an innovative biomedical industry with global influence.
Mr. Liu Ping, Deputy Director of Shanghai Municipal Commission of Economy and Informatization, attended the October event and inaugurated the Alliance. “Shanghai is taking on a significant mission to accelerate the pace toward becoming an innovation center for the biomedical industry,” said Liu Ping, “and to establish it as one of the three leading industries, gather elite and make breakthroughs as soon as possible.”
Shanghai is establishing a policy support system for the entire industry chain consisting of “R&D, clinical, manufacturing, and application,” making continuous improvements in the industrial layout, and taking multiple initiatives to promote the development model of "R&D in Zhangjiang + Shanghai Manufacturing," making every effort to build a world-class industrial cluster in the biopharmaceutical sector. As an important part of precision medicine, genetic testing is becoming one of the most promising industries in the field of health and life sciences.
The members of the Alliance are the core players in China’s genetic testing industry. The inauguration of the Alliance is also an important highlight of the International Biopharma Industry Week Shanghai 2021.
Members of the Alliance are expected to strengthen exchanges and collaborations in the field of genetic testing, effectively integrate resources across the industry chain, establish a platform for information sharing, set up an interactive mechanism with complementary win-win resources and shared results, and in addition, enhance the overall capability of the genetic testing industry and play a leading role in the Yangtze River Delta and even the whole world.
Mr. LI Zhaoshen, Academician of the First Affiliated Hospital of the People's Liberation Army Naval Medical University, representatives from the Shanghai Municipal Health Commission, the Shanghai Municipal Food and Drug Administration, and Shanghai Hospital Development Center, as well as the Shanghai Center for Clinical Laboratory also congratulated the establishment of the Alliance in various ways.
The Alliance is committed to improving the level of independent innovation in the field of genetic testing technology in China, accelerating the industrialization of technology, promoting collaboration among members, and enhancing group competitiveness.